Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 26, 2012. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction within a retirement plan rather than general corporate financial performance.
Material Changes
Following a revaluation of the cash element of the notional investment held within the US Retirement Savings Plan (notionally held in GSK American Depositary Shares), an increase in the notional allocation of ADSs occurred on November 23, 2012. The transaction price was $43.17 per ADS.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items related to the company's operations. It strictly reports a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Important Facts for Investors
- Transaction Date: November 23, 2012.
- Transaction Price: $43.17 per ADS.
- Involved Parties: Dr. M M Slaoui (Director) and Dr. K Slaoui (Connected Person).
- Allocation Details: Dr. M M Slaoui received 0 ADSs; Dr. K Slaoui received 4 ADSs.
- Context: The increase resulted from a revaluation of the cash element within the US Retirement Savings Plan.